Computational toxicology: An overview of the sources of data and of modelling methods

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 1, 2009, Pages 1-14

  Nigsch, Florian ^a   Macaluso, N J Maximilan ^a   Mitchell, John B O ^a   Zmuidinavicius, Donatas ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Adverse drug effect; Adverse drug reaction; Cheminformatics; Computational toxicology; Protein target prediction; Quantitative structure activity property relationships; Systems biology

Indexed keywords

PROTEIN STRUCTURE; PROTEIN TARGETING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SAFETY; SYSTEMS BIOLOGY; TOXICITY; ANIMAL; BIOLOGY; COMPUTER PROGRAM; DRUG TOXICITY; FACTUAL DATABASE; HUMAN; METHODOLOGY; TOXICOGENETICS; TOXICOLOGY;

ANIMALIA;

ANIMALS; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG TOXICITY; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SOFTWARE; SYSTEMS BIOLOGY; TOXICOGENETICS; TOXICOLOGY;

EID: 66449122787     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250802660467     Document Type: Review

References (113)

1. Balbus JM. Ushering in the new toxicology: Toxicogenomics and the public interest. Environ Health Perspect 2005;113:818-822 (Pubitemid 40984180)
2. Richard AM. Future of toxicology-predictive toxicology: An expanded view of "chemical toxicity". Chem Res Toxicol 2006;19:1257-1262
3. Azzaoui K, Hamon J, Faller B, et al. Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2007;2:874-880
4. Matthews EJ, Benz RD, Contrera JF. Use of toxicological information in drug design. J Mol Graph Mod 2000;18:605-615 (Pubitemid 32250646)
5. Selick HE, Beresford AP, Tarbit MH. The emerging importance of predictive ADME simulation in drug discovery. Drug Discov Today 2002;7:109-116 (Pubitemid 34088134)
6. Mendrick DL. Genomic and genetic biomarkers of toxicity. Toxicology 2008;245:175-181
7. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the food and drug administration, 1998-2005. Arch Intern Med 2007;167:1752-1759
8. Suter W. Predictive value of in vitro safety studies. Curr Opin Chem Biol 2006;10:362-366 (Pubitemid 44080653)
9. Waters M, Boorman G, Bushel P, et al. Systems toxicology and the Chemical Effects in Biological Systems (CEBS) knowledge base. EHP Toxicogenomics 2003;111:15-28 (Pubitemid 36157427)
10. Waters MD, Fostel JM. Toxicogenomics and systems toxicology: aims and prospects. Nat Rev Genet 2004;5:936-948
11. Castle AL, Carver MP, Mendrick DL. Toxicogenomics: a new revolution in drug safety. Drug Discov Today 2002;7:728-736
12. Benz RD. Toxicological and clinical computational analysis and the USFDA/CDER. Expert Opin Drug Metab Toxicol 2007;3:109-124
13. Richard AM, Yang C, Judson RS. Toxicity data informatics: Supporting a new paradigm for toxicity prediction. Toxicol Mech Method 2008;18:103-118
14. Registration, Evaluation, Authorisation and Restriction of Chemical substances - Available from: http://ec.europa.eu/environment/chemicals/reach/ reach-intro.htm
15. Richard AM, Gold LS, Nicklaus MC. Chemical structure indexing of toxicity data on the internet: moving toward a flat world. Curr Opin Drug Discov Devel 2006;9:314-325 (Pubitemid 43774160)
16. Liu B, Li S, Hu J. Technological advances in high-throughput screening. Am J Pharmacogenomics 2004;4:263-276 (Pubitemid 39145474)
17. Young DW, Bender A, Hoyt J, et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol 2008;4:59-68 (Pubitemid 350273652)
18. Adriaens ME, Jaillard M, Waagmeester A, et al. The public road to high-quality curated biological pathways. Drug Discov Today 2008;13:856-862
19. Barabasi A, Oltvai Z. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004;5:101-113 (Pubitemid 38160277)
20. Bundy J, Sidhu J, Rana F, et al. 'Systems toxicology' approach identifies coordinated metabolic responses to copper in a terrestrial non-model invertebrate, the earthworm Lumbricus rubellus. BMC Biol 2008;6:25
21. Ekins S, Andreyev S, Ryabov A, et al. A combined approach to drug metabolism and toxicity assessment. Drug Metab Dispos 2006;34:495-503 (Pubitemid 43290909)
22. Jalaie M, Holsworth DD. QT interval prolongation: and the beat goes on. Mini Rev Med Chem 2005;5:1083-1091 (Pubitemid 41723565)
23. Kerns E, Di L. Pharmaceutical profiling in drug discovery. Drug Discov Today 2003;8:316-323
24. Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov 2002;1:882-894 (Pubitemid 37361583)
25. Giuliano KA, Johnston PA, Gough A, Taylor DL. Systems cell biology based on high-content screening. Methods Enzymol 2006;414:601-619 (Pubitemid 44716243)
26. Li AP. Human hepatocytes: isolation, cryopreservation and applications in drug development. Chem Biol Interact 2007;168:16-29 (Pubitemid 46659921)
27. Li AP. In vitro evaluation of human xenobiotic toxicity: scientific concepts and the novel integrated discrete multiple cell co-culture (IdMOC) technology. ALTEX: Alternativen zu Tierexperimenten 2008;25:43-49
28. Parng C, Roy NM, Ton C, et al. Neurotoxicity assessment using zebrafish. J Pharmacol Toxicol Methods 2007;55:103-112 (Pubitemid 46048678)
29. Spicker J, Pedersen H, Nielsen H, Brunak S. Analysis of cell death inducing compounds. Arch Toxicol 2007;81:803-811 (Pubitemid 350043638)
30. Xing JZ, Zhu L, Gabos S, Xie L. Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicology in vitro: an international journal published in association with BIBRA 2006;20:995-1004 (Pubitemid 43959842)
31. Macgregor JT, Casciano D, Müller L. Strategies and testing methods for identifying mutagenic risks. Mutat Res 2000;455:3-20
32. Eisenbrand G, Pool-Zobel B, Baker V, et al. Methods of in vitro toxicology. Food Chem Toxicol 2002;40:193-236 (Pubitemid 34228905)
33. Nicholson RL, Welch M, Ladlow M, Spring DR. Small-molecule screening: advances in microarraying and cell-imaging technologies. ACS Chem Biol 2007;2:24-30 (Pubitemid 47490239)
34. Oberemm A, Onyon L, Gundert-Remy U. How can toxicogenomics inform risk assessment? Toxicol Appl Pharmacol 2005;207:592-598
35. Suter L, Babiss LE, Wheeldon EB. Toxicogenomics in predictive toxicology in drug development. Chem Biol 2004;11:161-171 (Pubitemid 38300287)
36. Mattes WB, Pettit SD, Sansone S, et al. Database development in toxicogenomics: issues and efforts. Environ Health Perspect 2004;112:495-505 (Pubitemid 38404561)
37. Suter L, Babiss LE, Wheeldon EB. Toxicogenomics in predictive toxicology in drug development. Chem Biol 2004;11:161-171 (Pubitemid 38300287)
38. Heijne WHM, Kienhuis AS, Van Ommen B, et al. Systems toxicology: applications of toxicogenomics,transcriptomics, proteomics and metabolomics in toxicology. Expert Rev Proteomics 2005;2:767-780 (Pubitemid 41492397)
39. Borgert CJ. Predicting interactions from mechanistic information: Can omic data validate theories? Toxicol Appl Pharmacol 2007;223:114-120
40. Gunther EC, Stone DJ, Gerwien RW, et al. Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. Proc Natl Acad Sci USA 2003;100:9608-9613 (Pubitemid 37033975)
41. Lord PG. Progress in applying genomics in drug development. Toxicol Lett 2004;149:371-375 (Pubitemid 38469855)
42. Tong W, Cao X, Harris S, et al. ArrayTrack: supporting toxicogenomic research at the US Food and Drug Administration National Center for Toxicological Research. Environ Health Perspect 2003;111:1819-1826 (Pubitemid 37526962)
43. Tong W, Harris S, Cao X, et al. Development of public toxicogenomics software for microarray data management and analysis. Mutat Res 2004;549:241-253 (Pubitemid 38553987)
44. Bushel P, Wolfinger R, Gibson G. Simultaneous clustering of gene expression data with clinical chemistry and pathological evaluations reveals phenotypic prototypes. BMC Syst Biol 2007;1:15
45. Fliri AF, Loging WT, Volkmann RA. Analysis of system structure-function relationships. ChemMedChem 2007;2:1774-1782
46. Waters M, Stasiewicz S, Merrick BA, et al. CEBS-Chemical Effects in Biological Systems: a public data repository integrating study design and toxicity data with microarray and proteomics data. Nucleic Acids Res 2008;36:D892-900 (Pubitemid 351149841)
47. Johnson DE, Rodgers AD. Computational toxicology: heading toward more relevance in drug discovery and development. Curr Opin Drug Discov Devel 2006;9:29-37 (Pubitemid 43099073)
48. Yang C, Benz RD, Cheeseman MA. Landscape of current toxicity databases and database standards. Curr Opin Drug Discov Devel 2006;9:124-133 (Pubitemid 43099082)
49. Yang C, Hasselgren C, Boyer S, et al. Understanding genetic toxicity through data mining: The process of building knowledge by integrating multiple genetic toxicity databases. Toxicol Mech Method 2008;18:277-295
50. Richard AM, Williams CR. Distributed structure-searchable toxicity (DSSTox) public database network: a proposal. Mutat Res 2002;499:27-52 (Pubitemid 34137072)
51. Waters KM, Pounds JG, Thrall BD. Data merging for integrated microarray and proteomic analysis. Brief Funct Genomic Proteomic 2006;5:261-272 (Pubitemid 46404130)
52. Von Korff M, Sander T. Toxicity-indicating structural patterns. J Chem Inf Model 2006;46:536-544
53. Foggia P, Limongiello A, Tufano F, Vento M. Learning graphs from examples: An application to the prediction of the toxicity of chemical compounds. Int J Pattern Recog Artif Intell 2006;20:883-896 (Pubitemid 44453415)
54. Kho R, Hodges JA, Hansen MR, Villar HO. Ring Systems in Mutagenicity Databases. J Med Chem 2005;48:6671-6678 (Pubitemid 41504723)
55. Llorens O, Perez J, Villar HO. Investigation of structural and electronic biases in mutagenic compounds. Int J Quant Chem 2002;88:107-117 (Pubitemid 34491397)
56. Simon-Hettich B, Rothfuss A, Steger-Hartmann T. Use of computer-assisted prediction of toxic effects of chemical substances. Toxicology 2006;224:156-162 (Pubitemid 43912977)
57. Benigni R, Netzeva TI, Benfenati E, et al. The expanding role of predictive toxicology: an update on the (Q)SAR models for mutagens and carcinogens. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2007;25:53-97 (Pubitemid 46393120)
58. Muster W, Breidenbach A, Fischer H, et al. Computational toxicology in drug development. Drug Discov Today 2008;13:303-310
59. Kruhlak NL, Contrera JF, Benz RD, Matthews EJ. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. Adv Drug Deliv Rev 2007;59:43-55 (Pubitemid 46204935)
60. Knize MG, Hatch FT, Tanga MJ, et al. A QSAR for the mutagenic potencies of twelve 2-amino-trimethylimidazopyridine isomers: structural, quantum chemical, and hydropathic factors. Environ Mol Mutagen 2006;47:132-146 (Pubitemid 43313741)
61. Matthews EJ, Kruhlak NL, Benz RD, et al. Combined use of MC4PC, MDL-QSAR, BioEpisteme, leadscope PDM, and derek for windows software to achieve high-performance, high-confidence, mode of action-based predictions of chemical carcinogenesis in rodents. Toxicol Mech Method 2008;18:189-206
62. Bhavani S, Nagargadde A, Thawani A, et al. Substructure-based support vector machine classifiers for prediction of adverse effects in diverse classes of drugs. J Chem Inf Model 2006;46:2478-2486 (Pubitemid 46008119)
63. Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today 2005;10:1421-1433 (Pubitemid 41483871)
64. Vedani A, Descloux AV, Spreafico M, Ernst B. Predicting the toxic potential of drugs and chemicals in silico: a model for the peroxisome proliferator-activated receptor gamma (PPAR gamma). Toxicol Lett 2007;173:17-23 (Pubitemid 47211705)
65. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-688 (Pubitemid 30650602)
66. Peraza MA, Burdick AD, Marin HE, et al. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci 2006;90:269-295
67. Nigsch F, Mitchell JBO. Toxicological relationships between proteins obtained from protein target predictions of large toxicity databases. Toxicol Appl Pharmacol 2008;231:225-234
68. Nigsch F, Bender A, Jenkins JL, Mitchell JBO. Ligand-Target Prediction using Winnow and Naïve Bayesian Algorithms and the Implications of Overall Performance Statistics. J Chem Inf Model 2008; accepted
69. Bender A, Scheiber J, Glick M, et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. ChemMedChem 2007;2:861-873
70. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006;6:546-558 (Pubitemid 43980543)
71. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006;16:127-136
72. Wermuth CG. Selective optimization of side activities: another way for drug discovery. J Med Chem 2004;47:1303-1314 (Pubitemid 38327456)
73. Nettles JH, Jenkins JL, Bender A, et al. Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. J Med Chem 2006;49:6802-6810
74. Lagunin A, Stepanchikova A, Filimonov D, Poroikov V. PASS: prediction of activity spectra for biologically active substances. Bioinformatics 2000;16:747-748 (Pubitemid 30843788)
75. Olah M, Mracec M, Ostopovici L, et al. WOMBAT: World of Molecular Bioactivity. In Chemoinformatics in Drug Discovery; Oprea, T. I., Ed.; Wiley-VCH: New York, 2004:223-239
76. Symyx, 2440 Camino Ramon, Suite 300, San Ramon, CA 94583
77. Inpharmatica Ltd, 60 Charlotte St., London W1T 2NU, UK
78. CEREP, 155 Boulevard Haussmann, 75008 Paris, France
79. Gunther S, Kuhn M, Dunkel M, et al. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res 2008;36:D919-22 (Pubitemid 351149845)
80. Kuhn M, Von Mering C, Campillos M, et al. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res 2008;36:D684-688 (Pubitemid 351149807)
81. Li H, Zhang H, Liu X, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008;9:104 (Pubitemid 351356783)
82. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36:D901-6 (Pubitemid 351149842)
83. Ji ZL, Han LY, Yap CW, et al. Drug Adverse Reaction Target Database (DART): proteins related to adverse drug reactions. Drug Saf 2003;26:685-690 (Pubitemid 36976130)
84. Rokosz LL, Beasley JR, Carroll CD, et al. Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert Opin Ther Targets 2008;12:883-903 (Pubitemid 352003327)
85. Prediction of Activity Spectra for Substances- http://195.178.207.233/ PASS/index.html
86. Nigsch F, Mitchell JBO. Toxicological relationships between proteins obtained from protein target predictions of large toxicity databases. Toxicol Appl Pharmacol 2008;231:225-234
87. Glick M, Davies JW, Jenkins JL. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J Chem Inf Model 2006;46:1124-1133 (Pubitemid 43999157)
88. Rogers D, Brown RD, Hahn M. Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J Biomol Screen 2005;10:682-686 (Pubitemid 41476802)
89. Jenkins JL, Glick M, Davies JW. A 3D Similarity Method for Scaffold Hopping from Known Drugs or Natural Ligands to New Chemotypes. J Med Chem 2004;47:6144-6159 (Pubitemid 39587240)
90. Zauhar RJ, Moyna G, Tian L, et al. Shape signatures: a new approach to computer-aided ligand-and receptor-based drug design. J Med Chem 2003;46:5674-5690 (Pubitemid 37543318)
91. Chekmarev DS, Kholodovych V, Balakin KV, et al. Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol 2008;21:1304-1314 (Pubitemid 351967396)
92. Keiser MJ, Roth BL, Armbruster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007;25:197-206 (Pubitemid 46227119)
93. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-996
94. Hopkins AL, Groom CR. The druggable genome. Nature Rev Drug Discov 2002;1:727-730 (Pubitemid 37361545)
95. Schlyer S, Horuk R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov Today 2006;11:481-493
96. Costanzi S. On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. J Med Chem 2008;51:2907-2914 (Pubitemid 351706019)
97. Chen Y, Zhi D. Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule. Proteins 2001;43:217-226
98. Available from: http://195.178.207.233/PASS/index.html
99. Gold ND, Jackson RM. Fold independent structural comparisons of protein-ligand binding sites for exploring functional relationships. J Mol Biol 2006;355:1112-1124 (Pubitemid 43012151)
100. Gold ND, Jackson RM. SitesBase: a database for structure-based protein-ligand binding site comparisons. Nucleic Acids Res 2006;34:D231-4
101. Gold ND, Jackson RM. A searchable database for comparing protein-ligand binding sites for the analysis of structure-function relationships. J Chem Inf Model 2006;46:736-742
102. Brakoulias A, Jackson RM. Towards a structural classification of phosphate binding sites in protein-nucleotide complexes: an automated all-against-all structural comparison using geometric matching. Proteins 2004;56:250-260 (Pubitemid 38850159)
103. Kuhn D, Weskamp N, Hüllermeier E, Klebe G. Functional classification of protein kinase binding sites using Cavbase. ChemMedChem 2007;2:1432-1447
104. Kellenberger E, Schalon C, Rognan D. How to measure the similarity between protein ligand-binding sites? Curr Comput Aided Drug Des 2008;4:209-220
105. Lai L. Prediction of potential drug targets based on simple sequence properties. BMC Bioinformatics 2007;8:353 (Pubitemid 350148941)
106. Bender A, Young DW, Jenkins JL, et al. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb Chem High Throughput Screen 2007;10:719-731 (Pubitemid 350099316)
107. Lapinsh M, Prusis P, Gutcaits A, et al. Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. Biochim Biophys Acta 2001;1525:180-190 (Pubitemid 32149991)
108. Strombergsson H, Kryshtafovych A, Prusis P, et al. Generalized modeling of enzyme-ligand interactions using proteochemometrics and local protein substructures. Proteins 2006;65:568-579 (Pubitemid 44583208)
109. Strombergsson H, Prusis P, Midelfart H, et al. Rough set-based proteochemometrics modeling of G-protein-coupled receptor-ligand interactions. Proteins 2006;63:24-34
110. Greene N. Computer systems for the prediction of toxicity: an update. Adv Drug Deliv Rev 2002;54:417-431 (Pubitemid 34260961)
111. Contrera JF, Kruhlak NL, Matthews EJ, Benz RD. Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. Regul Toxicol Pharmacol 2007;49:172-182 (Pubitemid 350103627)
112. Marchant CA, Briggs KA, Long A. In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for windows, meteor, and vitic. Toxicol Mech Method 2008;18:177-187
113. Hall LH, Kier LB. The E-state as the basis for molecular structure space definition and structure similarity. J Chem Inf Comput Sci 2000;40:784-791